vs

Side-by-side financial comparison of Genius Sports Ltd (GENI) and IDEX Corporation (IEX). Click either name above to swap in a different company.

IDEX Corporation is the larger business by last-quarter revenue ($886.9M vs $510.9M, roughly 1.7× Genius Sports Ltd). IDEX Corporation runs the higher net margin — 13.5% vs -12.3%, a 25.9% gap on every dollar of revenue. IDEX Corporation produced more free cash flow last quarter ($86.0M vs $69.6M). Over the past eight quarters, Genius Sports Ltd's revenue compounded faster (129.2% CAGR vs 5.4%).

Genius Sports is a sports data and technology company that provides data management, video streaming and integrity services to sports leagues, bookmakers and media companies.

IDEX can refer to several things, including:International Defence Exhibition, a biennial arms and defense technology sales exhibition IDEX Corporation, a publicly listed company that makes fluidics systems and specialty engineered products Ideanomics, a publicly traded company that trades under the IDEX ticker symbol.

GENI vs IEX — Head-to-Head

Bigger by revenue
IEX
IEX
1.7× larger
IEX
$886.9M
$510.9M
GENI
Higher net margin
IEX
IEX
25.9% more per $
IEX
13.5%
-12.3%
GENI
More free cash flow
IEX
IEX
$16.4M more FCF
IEX
$86.0M
$69.6M
GENI
Faster 2-yr revenue CAGR
GENI
GENI
Annualised
GENI
129.2%
5.4%
IEX

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
GENI
GENI
IEX
IEX
Revenue
$510.9M
$886.9M
Net Profit
$-63.0M
$120.0M
Gross Margin
25.2%
44.9%
Operating Margin
-11.5%
19.4%
Net Margin
-12.3%
13.5%
Revenue YoY
8.9%
Net Profit YoY
25.7%
EPS (diluted)
$1.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GENI
GENI
IEX
IEX
Q2 26
$886.9M
Q1 26
$899.1M
Q4 25
$510.9M
$899.1M
Q3 25
$335.4M
$878.7M
Q2 25
$215.2M
$865.4M
Q1 25
$119.7M
$814.3M
Q4 24
$413.0M
$862.9M
Q3 24
$285.8M
$798.2M
Net Profit
GENI
GENI
IEX
IEX
Q2 26
$120.0M
Q1 26
$128.3M
Q4 25
$-63.0M
$128.3M
Q3 25
$127.8M
Q2 25
$-47.3M
$131.6M
Q1 25
$-25.5M
$95.5M
Q4 24
$-85.5M
$123.2M
Q3 24
$-47.1M
$119.1M
Gross Margin
GENI
GENI
IEX
IEX
Q2 26
44.9%
Q1 26
43.1%
Q4 25
25.2%
43.1%
Q3 25
24.2%
44.5%
Q2 25
19.1%
45.3%
Q1 25
10.7%
45.3%
Q4 24
16.7%
42.5%
Q3 24
20.5%
44.3%
Operating Margin
GENI
GENI
IEX
IEX
Q2 26
19.4%
Q1 26
20.4%
Q4 25
-11.5%
20.4%
Q3 25
-15.3%
21.1%
Q2 25
-21.0%
21.7%
Q1 25
-20.3%
17.4%
Q4 24
-18.0%
19.2%
Q3 24
-13.9%
21.0%
Net Margin
GENI
GENI
IEX
IEX
Q2 26
13.5%
Q1 26
14.3%
Q4 25
-12.3%
14.3%
Q3 25
14.5%
Q2 25
-22.0%
15.2%
Q1 25
-21.3%
11.7%
Q4 24
-20.7%
14.3%
Q3 24
-16.5%
14.9%
EPS (diluted)
GENI
GENI
IEX
IEX
Q2 26
$1.61
Q1 26
$1.71
Q4 25
$1.71
Q3 25
$1.70
Q2 25
$1.74
Q1 25
$1.26
Q4 24
$1.61
Q3 24
$1.57

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GENI
GENI
IEX
IEX
Cash + ST InvestmentsLiquidity on hand
$280.6M
$586.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$724.5M
$4.0B
Total Assets
$1.1B
$6.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GENI
GENI
IEX
IEX
Q2 26
$586.2M
Q1 26
$580.0M
Q4 25
$280.6M
$580.0M
Q3 25
$110.2M
$593.8M
Q2 25
$110.2M
$568.2M
Q1 25
$110.2M
$594.1M
Q4 24
$100.3M
$620.8M
Q3 24
$100.3M
$633.2M
Total Debt
GENI
GENI
IEX
IEX
Q2 26
Q1 26
Q4 25
$1.8B
Q3 25
$1.9B
Q2 25
$1.9B
Q1 25
$2.0B
Q4 24
$2.0B
Q3 24
$2.1B
Stockholders' Equity
GENI
GENI
IEX
IEX
Q2 26
$4.0B
Q1 26
$4.0B
Q4 25
$724.5M
$4.0B
Q3 25
$572.4M
$4.0B
Q2 25
$572.4M
$4.0B
Q1 25
$572.4M
$3.9B
Q4 24
$573.0M
$3.8B
Q3 24
$573.0M
$3.8B
Total Assets
GENI
GENI
IEX
IEX
Q2 26
$6.9B
Q1 26
$6.9B
Q4 25
$1.1B
$6.9B
Q3 25
$792.3M
$7.0B
Q2 25
$792.3M
$6.9B
Q1 25
$792.3M
$6.8B
Q4 24
$775.7M
$6.7B
Q3 24
$775.7M
$7.0B
Debt / Equity
GENI
GENI
IEX
IEX
Q2 26
Q1 26
Q4 25
0.45×
Q3 25
0.48×
Q2 25
0.46×
Q1 25
0.50×
Q4 24
0.52×
Q3 24
0.55×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GENI
GENI
IEX
IEX
Operating Cash FlowLast quarter
$81.9M
Free Cash FlowOCF − Capex
$69.6M
$86.0M
FCF MarginFCF / Revenue
13.6%
9.7%
Capex IntensityCapex / Revenue
2.4%
2.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$33.5M
$654.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GENI
GENI
IEX
IEX
Q2 26
Q1 26
Q4 25
$81.9M
$209.5M
Q3 25
$-4.8M
$203.5M
Q2 25
$-1.2M
$161.7M
Q1 25
$-14.6M
$105.7M
Q4 24
$14.9M
$172.6M
Q3 24
$-9.2M
$205.3M
Free Cash Flow
GENI
GENI
IEX
IEX
Q2 26
$86.0M
Q1 26
$189.8M
Q4 25
$69.6M
$189.8M
Q3 25
$-14.2M
$188.7M
Q2 25
$-5.8M
$146.9M
Q1 25
$-16.0M
$91.4M
Q4 24
$11.3M
$157.1M
Q3 24
$-11.6M
$191.6M
FCF Margin
GENI
GENI
IEX
IEX
Q2 26
9.7%
Q1 26
21.1%
Q4 25
13.6%
21.1%
Q3 25
-4.2%
21.5%
Q2 25
-2.7%
17.0%
Q1 25
-13.4%
11.2%
Q4 24
2.7%
18.2%
Q3 24
-4.1%
24.0%
Capex Intensity
GENI
GENI
IEX
IEX
Q2 26
2.0%
Q1 26
7.1%
Q4 25
2.4%
2.2%
Q3 25
2.8%
1.7%
Q2 25
2.1%
1.7%
Q1 25
1.2%
1.8%
Q4 24
0.9%
1.8%
Q3 24
0.9%
1.7%
Cash Conversion
GENI
GENI
IEX
IEX
Q2 26
Q1 26
Q4 25
1.63×
Q3 25
1.59×
Q2 25
1.23×
Q1 25
1.11×
Q4 24
1.40×
Q3 24
1.72×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons